Chair: Raffaella Buzzetti (ITA) 18:15 – 18:20 Introduction Raffaella Buzzetti (ITA) 18:20 – 18:50 From Need to Innovation: Why Ketones Matter in Diabetes Management Kirsten Nørgaard
Chair: Jaime Almandoz (USA) 18:00 – 18:10 Opening the conversation on modern obesity treatments Jaime Almandoz (USA) 18:10 – 18:35 Oral and injectable semaglutide: weight
Chairs: Apostolos Tsapas (GRC), Melanie Davies (GBR) 18:00 – 18:05 Introduction Melanie Davies (GBR) 18:05 – 18:13 The Legacy Effect in T2D: Impact of early
18:00 – 18:05 Welcome and Introduction TBC 18:05 – 18:20 A Hidden T1D Population: The Rationale for Screening Dysglycemic Adults in Clinical Practice TBC 18:20
Chairs: Kamlesh Khunti (GBR), Alejandra Ramos (HND) 18:00 – 18:02 Introduction Kamlesh Khunti (GBR) 18:02 – 18:11 Real‑world patients, real‑world challenges: achieving glycemic control and
Chair: Partha Kar (GBR) 16:15 – 16:45 One technology, many realities: The real-world value of (predictive) CGM across the diabetes spectrum Partha Kar (GBR)Cameron Keighron
Chair: Alice Cheng (CAN) 16:15 – 16:18 Welcome and introduction Alice Cheng (CAN) 16:18 – 16:24 Why is MASH underdiagnosed? Alice Cheng (CAN) &
Chair: Naresh Kunamilli (GBR) 14:15 – 14:45 Rethinking Diabetes Diagnosis Targets: How CGM Can Inform Risk, Progression, Monitoring and Earlier Decision Making Naresh Kunamilli (GBR)
Chair: Partha Kar (GBR) 14:15 – 14:17 Welcome & Setting the Scene: Why Pathways Matter Now Partha Kar (GBR) 14:17 – 14:22 Building the Blueprint:
Chair: Fiona Adshead (GBR) 11:30 – 11:40 An underestimated impact: The environmental footprint in diabetes Fiona Adshead (GBR) 11:40 – 11:50 Moving towards more sustainability